Humira Buyers Say They've Proven AbbVie's 'Patent Thicket'

By Nadia Dreid · November 25, 2019, 9:31 PM EST

AbbVie shouldn't be able to escape first-of-its-kind litigation accusing the pharmaceutical giant of building a "patent thicket" around its immunosuppressant Humira in order to block cheaper biosimilars from coming onto the...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

In Re: Humira (Adalimumab) Antitrust Litigation

Case Number

1:19-cv-01873

Court

Illinois Northern

Nature of Suit

410(Anti-Trust)

Date Filed

March 18, 2019